Roche ends autoimmune deal with Actelion

Actelion Ltd. (SIX:ATLN) said Roche (SIX:ROG; OTCQX:RHHBY) ended a 2006 deal to develop and commercialize Actelion's sphingosine 1-phosphate receptor 1 ( S1PR1, S1P1, EDG1) agonists for autoimmune indications. According to Actelion, Roche made the decision following a comprehensive portfolio review. Actelion plans to continue development of the program's lead, ACT-128800, which is in Phase II testing for psoriasis and multiple sclerosis. ...